Verona Pharma’s President and CEO David Zaccardelli Wins Executive of the Year SCRIP Award
17 11월 2023 - 4:00PM
Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the
“Company”), announces its President and CEO, David Zaccardelli, has
won ‘Executive of the Year 2023’ at the SCRIP Awards in recognition
of his exemplary leadership.
David Zaccardelli, Pharm. D., President and CEO
of Verona Pharma said: “I am honored to receive this prestigious
award and would like to thank the dedicated and talented team at
Verona Pharma for their efforts to bring our first-in-class
treatment to the millions of chronic obstructive pulmonary disease
(“COPD”) patients worldwide who remain symptomatic. Ensifentrine is
under review by the US Food and Drug Administration for the
maintenance treatment of COPD and this achievement would not have
been possible without their hard work.”
For further information please contact:
Verona Pharma plc |
US Tel: +1-833-417-0262UK Tel: +44 (0)203 283 4200 |
Victoria Stewart, Senior Director of Investor Relations and
Communications |
IR@veronapharma.com |
Argot PartnersUS Investor Enquiries |
Tel: +1-212-600-1902verona@argotpartners.com |
Ten Bridge CommunicationsInternational / US Media
Enquiries |
Tel: +1-312-523-5016tbcverona@tenbridgecommunications.com |
Leslie Humbel |
|
About Verona Pharma
Verona Pharma is a clinical-stage
biopharmaceutical company focused on developing and commercializing
innovative therapies for the treatment of chronic respiratory
diseases with significant unmet medical needs. If successfully
developed and approved, Verona Pharma’s product candidate,
ensifentrine, has the potential to become the first non-steroidal
therapy for the treatment of respiratory diseases that combines
bronchodilator and anti-inflammatory activities in one molecule.
The Company has evaluated nebulized ensifentrine in its Phase 3
clinical program ENHANCE (“Ensifentrine as a Novel inHAled
Nebulized COPD thErapy”) for COPD maintenance treatment.
Ensifentrine met the primary endpoint in both ENHANCE-1 and
ENHANCE-2 trials demonstrating statistically significant and
clinically meaningful improvements in lung function. In addition,
ensifentrine substantially reduced the rate and risk of COPD
exacerbations in pooled analysis from ENHANCE-1 and ENHANCE-2. In
the third quarter of 2023, the US Food and Drug Administration
accepted for review the Company’s NDA for ensifentrine for the
maintenance treatment of patients with COPD and assigned a PDUFA
target action date of June 26, 2024. Two additional
formulations of ensifentrine have been evaluated in Phase 2 trials
for the treatment of COPD: dry powder inhaler (“DPI”) and
pressurized metered-dose inhaler (“pMDI”). Ensifentrine has
potential applications in cystic fibrosis, non-cystic fibrosis
bronchiectasis, asthma and other respiratory diseases. For more
information, please visit www.veronapharma.com
Verona Pharma (NASDAQ:VRNA)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Verona Pharma (NASDAQ:VRNA)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024